An interventional study of CPAP treatment in Sleep Apnea, Continuous Positive Airway Pressure and Prostaglandins, sponsored by Kyoto University. Completed at 1 site in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2012-01-26.
Sponsored by Kyoto University · Not applicable, Interventional, and Treatment
The purpose of this study is to evaluate the associations of circadian variations, sleep architecture, hypertension and prostanoids in the patients with sleep apnea. In addition, the patients introduced to continuous positive airway pressure(CPAP) treatment, the effects of CPAP are also evaluated.
Obstructive sleep apnea (OSA) is characterized by repetitive episodes of upper airway obstruction during sleep that provoke frequents arousals, sleep fragmentation, oxygen desaturation, and excessive daytime sleepiness. OSA may contribute to the development of systemic hypertension, cardiovascular disease. Many studies has reported a crucial role for the prostaglandin D system in sleep regulation. In addition, it has been described urinary or blood levels of prostaglandins was higher in the patients with hypertension, diabetes mellitus, and these values were associated with the severity of coronary artery disease. However, the relation between alterations of prostaglandin D system and sleep architecture, sleepiness, and clinical outcomes such as hypertension, arteriosclerosis in the patients with OSA are not known. Additionally, after CPAP treatment, we will investigate the association between change of prostaglandin system and sleep architecture, sleepiness, clinical outcomes.
2,183 studies on the registry are indexed under Sleep Apnea Syndromes; 284 are open to participants now.
This study's enrollment of 64 is above the median of 53 across 1,400 interventional studies indexed under Sleep Apnea Syndromes.
Browse Sleep Apnea Syndromes studies →Kyoto University is the lead sponsor of 22 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The subjects introduced with CPAP treatment
Device: CPAP treatment
maintains upper airway patency and minimizes the obstructive events
Also known as: REMstar (Respironics), Auto Set(Resmed), Goodnight (Tyco Healthcare)
Prostaglandins in the urine and blood
Time frame: baseline, and 2days, 3 months after CPAP
polysomnography measurements
Time frame: baseline, and 2days, 3 months after CPAP
sleepiness and health-related quality of life
Time frame: baseline, and 2days, 3 months after CPAP
Clinical measurements (blood pressure, heart rate, sympathetic activity etc)
Time frame: baseline, and 2days, 3 months after CPAP
serum and urinary biomarker (inflammation, oxidative stress etc.)
Time frame: baseline, and 2days, 3 months after CPAP
endothelial function
Time frame: baseline, and 2days, 3 months after CPAP
The record gives a start of May 2010, a primary completion of Oct 2011 and a completion of Jan 2012. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Kyoto University